Figure S1: Flowchart of PETACC8 cohort analysis


*Emile J-F, Eur J Cancer, 2017.

# Figure S2: Kaplan-Meier of interest

A

P = 0.0056 HR = 0.7070 [0.54056-0.92469]

Number at risk	763	714	622	590	533	505
	255	228	189	170	158	152

B

P = 0.0009 HR = 1.530 [1.1702-2.0017]

Number at risk	255	231	188	170	153	142
	763	709	620	587	550	513

C

P = 0.0008 HR = 0.6060 [0.4680-0.7847]

Number at risk	255	242	223	210	196	181
	763	698	586	547	507	474

D

P < 0.0001 HR = 1.7940 [1.4275-2.2544]

Number at risk	509	461	377	345	315	293
	509	479	432	412	387	362

E

P = 0.01369 HR = 0.6999 [0.5401-0.9069]

Number at risk	255	245	217	204	188	177
	763	695	592	553	515	478

F

P < 0.0001 HR = 1.714 [1.3642-2.1543]

Number at risk	509	462	375	349	319	293
	509	478	434	408	383	362

Figure S3: Correlation between immune parameters and areas of interest

Figure S4: Pronostic value of immune T cells analysis

A

P = 0.9047 HR = 1.117 [0.8892-1.404]

| Number at risk | 509 | 474 | 402 | 375 | 344 | 319 |
| | 509 | 467 | 408 | 383 | 360 | 336 |

B

P = 0.0054 HR = 1.385 [1.102-1.74]

| Number at risk | 509 | 466 | 393 | 363 | 336 | 314 |
| | 509 | 475 | 417 | 395 | 368 | 341 |

Figure S5:Correlation between TC-CD3⁺, DGMate and relative stroma area

Figure S5: Correlation between TC-CD3⁺, DGMate and relative stroma area

Figure S6: Survival comparision of composite variables depending on adjuvant chemotherapy

A

B